Mark Sirgo, president and CEO of BioDelivery Sciences International (NASDAQ: [[ticker:BDSI]]), will retire at the end of the year, the Raleigh, NC, pharmaceutical company has announced. But Sirgo will remain vice chairman of BDSI’s board of directors. The company said that the board will work with Sirgo to find his successor. Sirgo, who has been president and CEO of BDSI since 2005, led the company to FDA approvals of treatments for chronic pain, cancer pain, and opioid dependence.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
